Image Place holder

Jyoti Raychaudhuri, MD

Specialty: Hematology/Oncology
Sub Specialty: Medical Oncology, Hematology
Program: Malignant Hematology and Cellular Therapy at Memorial Healthcare System


Cancer Focus: Hodgkin Lymphoma, Leukemia, Multiple Myeloma-Plasma Cell Tumor, Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma

Dr. Jyotishankar Raychaudhuri is a blood and marrow transplant specialist at Moffitt Malignant Hematology and Cellular Therapy at Memorial Healthcare System in Pembroke Pines. Dr. Raychaudhuri earned his medical degree at All India Institute of Medical Sciences in New Delhi, India. He completed residencies in radiology and radiotherapy, internal medicine, and pathology in India, as well as a residency and fellowship in internal medicine at Lincoln Hospital, affiliated with New York Medical School. He completed another fellowship in hematology/oncology at Winthrop University Hospital in New York, and served as a post-doctoral fellow in a molecular biology and biochemistry lab at Cold Spring Harbor Laboratory in New York. In addition to providing patient care, Dr. Raychaudhuri also teaches and trains medical students and young physicians. He has taught at various institutions including New York Medical College at Metropolitan Hospital, Cornell University Medical Center, Moffitt Cancer Center and the USF Morsani College of Medicine. He is also a manuscript reviewer for the journal of Clinical Myeloma and Lymphoma and a member of the Acute Leukemia Writing Committee, as part of the Center for International Blood & Marrow Transplant Research (CIBMTR). Most recently, Dr. Raychaudhuri served as a senior consultant for Blood and Marrow Transplantation at Apollo Indraprastha Hospital in New Delhi, India. He has also served as assistant professor of Blood and Marrow Transplantation at the H. Lee Moffitt Cancer Center & Research Institute in Tampa.

Education & Training


  • Lincoln Hospital, New York Medical College - Internal Medicine
  • Winthrop University Hospital Mineola, SUNY at Stony Brook - Hematology/Oncology
  • Cold Spring Harbor Laboratory - Molecular Biology and Biochemistry


  • All India Institute of Medical Sciences (New Delhi, India) - Radiology and Radiotherapy
  • Sir Ganga Ram and Associated Hospitals (New Delhi, India) - Internal Medicine
  • King Edward Memorial Hospital, Bombay University (Bombay, India) - Pathology
  • Lincoln Hospital, New York Medical College - Internal Medicine
Participating Trials

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.


  • Nishihori T, Alekshun TJ, Shain K, Sullivan DM, Baz R, Perez L, Pidala J, Kharfan-Dabaja MA, Ochoa-Bayona JL, Fernandez HF, Yarde DN, Oliveira V, Fulp W, Han G, Kim J, Chen DT, Raychaudhuri J, Dalton W, Anasetti C, Alsina M. Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma. Brit J Haematol. 2012 Jun.157(5):553-563. Pubmedid: 22449149. Pmcid: PMC4030553.
  • Santarone S, Pidala J, Di Nicola M, Field T, Alsina M, Ayala E, Janssen W, Kharfan-Dabaja MA, Ochoa L, Perez L, Perkins J, Raychaudhuri J, Fernandez H, Anasetti C. Fludarabine and pharmacokinetic-targeted busulfan before allografting for adults with acute lymphoid leukemia. Biol Blood Marrow Tr. 2011 Oct.17(10):1505-1511. Pubmedid: 21385623.
  • Liu JJ, Zhang L, Ayala E, Field T, Ochoa-Bayona JL, Perez L, Bello CM, Chervenick PA, Bruno S, Cultrera JL, Baz RC, Kharfan-Dabaja MA, Raychaudhuri J, Sotomayor EM, Sokol L. Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: a single institutional experience and literature review. Leuk Res. 2011 Dec.35(12):1571-1577. Pubmedid: 21752466.
  • Hoda D, Pidala J, Salgado-Vila N, Kim J, Perkins J, Bookout R, Field T, Perez L, Ayala E, Ochoa-Bayona JL, Raychaudhuri J, Alsina M, Greene J, Janssen W, Fernandez HF, Anasetti C, Kharfan-Dabaja MA. Sirolimus for treatment of steroid-refractory acute graft-versus-host disease. Bone Marrow Transplant. 2010 Aug.45(8):1347-1351. Pubmedid: 19966849.
  • Raychaudhuri J, Cualing H, Haider K, Kharfan-Dabaja M. Granulocytic sarcoma and chronic lymphocytic leukemia of the gastrointestinaltract after allogeneic hematopoietic cell transplantation mimickinggraft-versus-host disease. Leuk Lymphoma. 2008 Feb.49(2):350-352. Pubmedid: 18231925.

Patient Comments
Overall Satisfaction

patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments